MedPath

Intravenous immunoglobulin or intralipid treatment for recurrent pregnancy loss or implantation failures women with NK cell abnormality

Not Applicable
Recruiting
Conditions
Recurrent pregnancy loss, implantation failure
Registration Number
JPRN-UMIN000038952
Lead Sponsor
Hyogo College of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Untreated other causes of infertility or RPL Allergy for IVIG or intralipid

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
For recurrent pregnancy loss women with NK cell abnormality: ongoing pregnancy rate at 22 weeks of pregnancy For implantation failure women with NK cell abnormality: pregnancy rate and ongoing pregnancy rate at 22 weeks of pregnancy
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath